Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Ovarian Neoplasms

  Free Subscription


15.03.2021

2 Int J Cancer
1 Int J Gynaecol Obstet
1 Int J Oncol
2 Lancet Oncol


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Int J Cancer

  1. REIJNEN C, Kusters-Vandevelde HVN, Ligtenberg MJL, Bulten J, et al
    Molecular profiling identifies synchronous endometrial and ovarian cancers as metastatic endometrial cancer with favorable clinical outcome.
    Int J Cancer. 2020 Feb 5. doi: 10.1002/ijc.32907.
    PubMed         Abstract available

  2. FELIX AS, McLaughlin EM, Caan BJ, Cohn DE, et al
    Guideline-concordant endometrial cancer treatment and survival in the Women's Health Initiative Life and Longevity After Cancer study.
    Int J Cancer. 2019 Oct 16. doi: 10.1002/ijc.32740.
    PubMed         Abstract available


    Int J Gynaecol Obstet

  3. KHADRAOUI W, Tierney C, Chung S, Mutlu L, et al
    Risk-stratifying clinicopathologic criteria for ovarian preservation in premenopausal women with early stage low-risk endometrial cancer.
    Int J Gynaecol Obstet. 2020 Jun 7. doi: 10.1002/ijgo.13254.
    PubMed         Abstract available


    Int J Oncol

  4. GUO F, Zhang K, Li M, Cui L, et al
    miR5083p suppresses the development of ovarian carcinoma by targeting CCNA2 and MMP7.
    Int J Oncol. 2020 Apr 27. doi: 10.3892/ijo.2020.5055.
    PubMed         Abstract available


    Lancet Oncol

  5. SHI T, Zhu J, Feng Y, Tu D, et al
    Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.
    Lancet Oncol. 2021 Mar 8. pii: S1470-2045(21)00006.
    PubMed         Abstract available

  6. RICHARDSON DL
    Should we or should we not? Secondary debulking in ovarian cancer.
    Lancet Oncol. 2021 Mar 8. pii: S1470-2045(21)00024.
    PubMed        


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: